http://www.acc.org/Feed?clinicalTopicID=2e96633a-1c99-4f33-9eda-83554d60f058 Clinical Topic Feed: Interventions and Coronary Artery Disease en /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-protavi-acc-2026 Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study presented in a Late-Breaking Clinical Trial session... 1774818600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/18/00/50/eagles-eye-view-18mar2025 In this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. 1773842400000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/10/16/54/RENOVATE-COMPLEX-PCI-Benefit-With-Intravascular In the multicenter open-label superiority trial, Joo Myung Lee, MD, MPH, PhD, FACC, et al., randomized 1,639 patients (mean age 66; 20% women) with complex coronary artery lesions across 20 hospitals in South Korea 2:1 to either intravascular imaging-guided PCI (n=1,092) or angiography-guided PCI (n=547). Of the overall cohort, 49% presented with stable ischemic heart disease and 51% with an acute coronary syndrome (ACS). Thirty-one percent had three or more characteristics of complex coronary artery lesions in the target lesion. The most common was long coronary lesion, followed by multivessel PCI, true bifurcation lesion and chronic total occlusion. 1773162180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/04/12/02/Extended-DAPT-in-Multivessel-CAD The DAPT-MVD (Dual Antiplatelet Therapy in Patients With Coronary Multi-Vessel Disease) trial was a multicenter, randomized, open-label study in China designed to assess whether extending dual antiplatelet therapy (DAPT) beyond 12 months provides additional benefit for patients with multivessel coronary artery disease (CAD)... 1772647140000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1772370600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/24/16/30/eagles-eye-view-24feb2025 In this week’s View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. 1772031600000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/17/14/32/TUXEDO-2 Ticagrelor was not shown to be noninferior to prasugrel for the reduction of the primary composite endpoint of death, nonfatal myocardial infarction (MI), stroke or major bleeding at one year in patients with diabetes and multivessel coronary disease (MVD) undergoing PCI... 1771431780000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/03/17/39/eagles-eye-view-04feb2025 In this week’s View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. 1770217200000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/03/11/30/Shocking-the-Rock-With-Coronary-Intravascular-Lithotripsy Intravascular lithotripsy (IVL) is a groundbreaking technology in percutaneous coronary intervention (PCI) for treating calcified coronary artery disease (CAD). 1770133920000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/01/28/02/51/ORBITA-2-Secondary-Analysis Age had no effect on PCI success in reducing angina frequency, but older adults may experience greater symptom relief, according to a post-hoc of the ORBITA-2 trial published Jan. 27 in JACC. 1769608800000 Articles and Stories